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The importance of Leucine-Rich Repeat Kinase 2 (LRRK2) to mature neurons is well-
established, since mutations in PARK8, the gene encoding LRRK2, are the most common 
known cause of Parkinson’s disease. Nonetheless, despite the LRRK2 knockout mouse 
having no overt neurodevelopmental defect, numerous lines of in vitro data point towards a 
central role for this protein in neurogenesis. Roles for LRRK2 have been described in many 
key processes, including neurite outgrowth and the regulation of microtubule dynamics. 
Moreover, LRRK2 has been implicated in cell cycle control, suggesting additional roles in 
neurogenesis that precede terminal differentiation. However, we contend that the suggested 
function of LRRK2 as a scaffolding protein at the heart of numerous Wnt signaling cascades 
provides the most tantalizing link to neurogenesis in the developing brain. Numerous lines of 
evidence show a critical requirement for multiple Wnt pathways in the development of 
certain brain regions, not least the dopaminergic neurons of the ventral mid-brain. In 
conclusion, these observations indicate a function of LRRK2 as a subtle yet critical mediator 
of the action of Wnt ligands on developing neurons. We suggest that LRRK2 loss- or gain-of-
function are likely modifiers of developmental phenotypes seen in animal models of Wnt 
signaling deregulation, a hypothesis that can be tested by cross-breeding relevant genetically 
modified experimental strains. 
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Leucine-rich repeat kinase 2: LRRK2 
Leucine-rich repeat kinase 2 (LRRK2) is a protein that has been the subject of extensive 
research in recent years. This interest stems from the identification of LRRK2 as the product 
of the human PARK8 gene, previously implicated as the cause of a familial form of 
Parkinson’s disease in genetic linkage studies (Paisán-Ruíz et al., 2004; Zimprich et al., 
2004). Furthering interest in LRRK2, PARK8 has subsequently been associated with cancer, 
leprosy and Crohn’s disease (Hassin-Baer et al., 2009; Van Limbergen et al., 2009; Zhang et 
al., 2009). The importance of LRRK2 to these diseases will not be discussed further as the 
relevance to neuronal biology is limited. Nonetheless, the association of a single gene with 
four distinct medical conditions serves to highlight the complexity of LRRK2 function. 
Parkinson’s disease is a currently incurable late-onset neurodegenerative disorder with 
increasing public health implications in an aging population (Gasser, 2010). Therefore 
uncovering the molecular events causing this condition with the ultimate aim of identifying 
therapeutic targets for disease modifying treatment has gained in importance. The PARK 
genes mutated in patients with familial Parkinson’s disease represent an obvious starting 
point for this research. Although PARK8 is just one of more than a dozen loci linked to 
Parkinson’s disease, certain lines of evidence indicate that LRRK2 is of special relevance. 
Globally PARK8 mutations are estimated to contribute to 1-5% of Parkinson’s disease cases, 
which represents the greatest contribution from any known genetic or environmental cause 
(Kumari & Tan, 2009). In some populations, most notably North African Berbers, PARK8 
mutations are very common and account for as much as two-fifths of all Parkinson’s disease 
cases (Jasinska-Myga et al., 2010; Lesage et al., 2005). Importantly, patients with PARK8 
mutations exhibit symptoms that are clinically indistinguishable from the more common 
idiopathic form of Parkinson’s disease, while observed post-mortem brain pathologies are 
also largely identical (Zimprich et al., 2004). Thus, it seems likely that LRRK2 also plays a 
role in an as yet undetermined process that is deregulated very early in the pathogenesis of 
idiopathic Parkinson’s disease (Berwick & Harvey, 2011; Kumari & Tan, 2009). 
From a biochemical perspective, there are two immediate observations to be made about 
LRRK2. First, LRRK2 is a large (2527 amino acid) protein, containing multiple protein-
protein interaction domains (Fig 1). Unsurprisingly, a vast number of interaction partners 
have been reported and LRRK2 has been suggested to function primarily as scaffolding 
protein (Berwick & Harvey, 2011; Lewis & Manzoni, 2012). Indeed, the breadth of reported 
interactors is so wide that LRRK2 probably functions in a number of distinct multi-protein 
complexes. Second, LRRK2 contains two separate enzymatic activities: serine-threonine 
phosphorylation (kinase activity) and guanine triphosphate hydrolysis (GTPase activity). 
Understandably, this has lead to the suggestion of alternative roles for LRRK2 as a 
‘conventional’ signaling protein, either functioning as a protein kinase or in an analogous 
manner to small GTPases such as Ras or Rac (Berwick & Harvey, 2011).  
A detailed review of LRRK2 function is beyond the scope of this article, but what is most 
important to stress is that the function of LRRK2 remains unclear and in many cases is 
controversial. For example, eight years of research have failed to find a reproducible kinase 
substrate other than LRRK2 itself, while there is still no agreement on whether the GTPase 
activity controls kinase activity or vice versa. It seems probable therefore that these functions 
are interdependent. In any case, the enzymatic activities of LRRK2 are certainly of some 
importance in the physiological and pathological function of this protein. To date all 
described PARK8 mutations clearly segregating with Parkinson’s disease cause changes in 
the GTPase or kinase domains, but not in any of the protein-protein interaction domains (Fig. 
1). Over-expression of LRRK2 in cultured cells and transgenic animals has been widely 
reported to cause cytotoxicity (Biosa et al., 2012; Greggio et al., 2006; Iaccarino et al., 2007; 
Smith et al., 2006; Stafa et al., 2012; West et al., 2007; Xiong et al., 2010). Whether this 
observation reflects an artifactual effect of overexpressing this large protein is unclear. 
Nonetheless, it is now generally accepted that this observed cytotoxicity is enhanced by 
PARK8 mutations but ameliorated by loss of LRRK2 kinase or GTPase activity. In light of 
this, much work has been predicated on the idea that pathological effects of PARK8 
mutations require LRRK2 kinase activity, and in consequence a great deal of effort has gone 
into developing a pharmacological inhibitor of LRRK2 kinase activity (Ray & Liu, 2012). 
However, although the common G2019S mutation has been reproducibly shown to elicit 
increased LRRK2 kinase activity this mutation appears unique: all other mutations 
segregating with Parkinson’s disease have no reproducible effect on kinase activity (Greggio 
& Cookson, 2009). Furthermore, the G2385R mutation, a risk factor within Asian 
populations, has been reported to have decreased kinase activity (Rudenko et al., 2012). Thus 
LRRK2 kinase activity appears to regulate the function of this protein, but whether increased 
kinase activity is responsible for pathogenesis in PARK8 patients remains to be established. 
In conclusion, we favor a model where LRRK2 functions primarily as a scaffold that 
nucleates multiple protein complexes, but where protein function is nonetheless dependent on 
LRRK2 kinase and GTPase activities.  
Despite considerable disagreement about LRRK2 function at the biochemical level, cell 
biological and transgenic animal studies have allowed advances to be made. In the following 
section we review aspects of LRRK2 biology where there are sufficient data to paint an 
overall picture that is beyond dispute, even if specific details are controversial or not yet 
known. We value the importance of work performed in lower organisms and will mention 
data obtained from these systems where pertinent, however this review will focus on 
mammalian data. This distinction is justified since mammals express two LRRK2 proteins, 
LRRK1 and LRRK2, which despite strong similarities in sequence and structure appear to 
have contrasting functions. Lower organisms, in particular Drosophila melanogaster and 
Caenorhabditis elegans, encode a single LRRK protein, which is thus the ortholog of both 
LRRK1 and LRRK2. As we outline, there is sufficient evidence in existence to make roles 
for LRRK2 in three processes that underlie neurogenesis beyond debate. These are roles in 
synaptic and endosomal vesicle trafficking, macroautophagy and regulation of microtubule 
dynamics are illustrated in Figure 2. Furthermore, an effect of LRRK2 on neurite outgrowth – 
a direct measure of the latter stages of neurogenesis – is extremely well supported. Coupled 
with growing evidence of roles in adult neurogenesis and in proliferation we contend that 
these data make a strong case for a central role for LRRK2 in multiple stages of 
neurogenesis.  
Roles for LRRK2 in functions underlying neurogenesis 
Regulated membrane trafficking events underlie many key processes involved in 
neurogenesis. These include requirements for endocytosis for the proper function of 
neurogenic signaling pathways, such as Notch and Wnt cascades, and membrane receptors 
involved in axonal outgrowth (Blitzer & Nusse, 2006; Le Borgne, 2006; Winckler & Yap, 
2011). Importantly, roles for LRRK2 in membrane trafficking events are supported by data 
extending from early reports placing LRRK2 protein on cellular membranes (Biskup et al., 
2006; Hatano et al., 2007) to evidence of vacuolation in LRRK2 knockout mouse kidney 
cells (Tong et al., 2012). Intriguingly, the kinase activity of LRRK2 appears to be enhanced 
at membranes (Berger et al., 2010), while the distribution of LRRK2 between membrane and 
cytosolic fractions can be regulated by extracellular stimuli (Berwick & Harvey, 2012a). 
These observations suggest that LRRK2 plays an active role in membrane trafficking events, 
and is not simply present as a by-stander.  
The precise membranous compartments and/or vesicles LRRK2 inhabits remains contentious 
since many have been suggested, however membrane compartments involved in two cellular 
processes – pre-synaptic vesicle trafficking and macroautophagy – stand prominent. Evidence 
of a role for LRRK2 in the trafficking of pre-synaptic vesicles comes from multiple 
experimental techniques. These include localization of LRRK2 to vesicles in synaptic 
terminals by confocal and electron microscopy (Piccoli et al., 2011; Xiong et al., 2010), 
demonstrable electrophysiological defects following knock-down or over-expression of 
LRRK2 in cultured neurons (Piccoli et al., 2011; Shin et al., 2008), and biochemical 
interaction and co-localization of LRRK2 with the early endosomal marker Rab5b (Shin et 
al., 2008). The function of LRRK2 in pre-synaptic vesicular compartments remains to be 
determined, although a recent report that the LRRK2 homolog in Drosophila phosphorylates 
endophilinA proteins is promising (Matta et al., 2012). 
A wealth of data implicate LRRK2 in macroautophagy, the process by which damaged 
organelles and protein aggregates are ‘consumed’ by engulfment by membranous 
autophagosomes that subsequently fuse with lysosomes (Codogno et al., 2012). 
Macroautophagy is traditionally considered a mechanism of cellular homeostasis and 
regulated cell death. However, neural development is especially dependent on this process, 
most likely for mediating the extensive physical remodeling required (Cecconi et al., 2007; 
Cecconi & Levine, 2008). Studies performed using mouse models of LRRK2 dysfunction 
have been particularly revealing, since multiple observations show impaired macroautophagy 
in the kidney of Lrrk2 null animals (Herzig et al., 2011; Tong et al., 2012; Tong et al., 2010). 
These data include increased numbers of lysosomes and related structures, and an 
accumulation of the macroautophagy substrates p62 protein and lipofuscin granules. Much of 
this kidney phenotype appears to be replicated in transgenic mice that over-express LRRK2 
containing an artificial kinase-inactivating mutation (Herzig et al., 2011). In agreement with 
these observations, over-expression of LRRK2 impacts upon the autophagic pathway in 
HEK293 cells (Alegre-Abarrategui et al., 2009; Gómez-Suaga et al., 2012). Importantly, 
published data also support a role for LRRK2 in macroautophagic processes in the central 
nervous system. Most notably, brains from aged transgenic mice that over-express human 
LRRK2 variants containing either the R1441C or G2019S PARK8 mutations have an 
accumulation of autophagic vacuoles (Ramonet et al., 2011). This observation appears to be 
corroborated in vitro, where over-expression of G2019S has similar effects in cultured 
primary neurons or differentiated SH-SY5Y cells (MacLeod et al., 2006; Plowey et al., 
2008). 
Studies in Drosophila suggest another connection between LRRK2 and macroautophagy: via 
interaction with the small GTPase Rab7 (Dodson et al., 2012). Rab7 is well established as a 
key regulator of the fusion step between macroautophagic organelles and lysosomes 
(Codogno et al., 2012). If this observation can be replicated in mammalian systems it would 
be a fascinating result, since Rab7 is also involved in the latter stages of endocytosis, 
mediating late endosomal maturation and fusion with the lysosome (Wang et al., 2011). As 
mentioned above, LRRK2 has also been reported to interact with Rab5b (Shin et al., 2008). 
Since Rab5 proteins link pre-synaptic vesicle trafficking with early stages of endocytosis and 
Rab7 links autophagy with late-stage endocytosis, these observations together connect 
LRRK2 with the entire endocytic pathway.  
In neurons endocytic vesicles can be trafficked over huge distances, particularly in axons. 
The importance of microtubules for this process is well described (Perlson et al., 2010). It is 
therefore interesting that an association between LRRK2 and microtubules has been reported 
by a large number of groups (Biskup et al., 2006; Dzamko et al., 2010; Gandhi et al., 2008; 
Gillardon, 2009a; Gillardon, 2009b; Gloeckner et al., 2006; Kawakami et al., 2012; Kett et 
al., 2012; Sancho et al., 2009; Sheng et al., 2012). This physical association appears highly 
relevant to neurogenesis as LRRK2 has been reported to co-localize with microtubules within 
growth cones (Sancho et al., 2009).  
The nature of the LRRK2-microtubule interaction is still unresolved. For example there are 
conflicting reports about whether inhibition of LRRK2 kinase activity promotes (Dzamko et 
al., 2010) or weakens (Kett et al., 2012) the association. However, a role for LRRK2 in 
microtubule dynamics seems beyond dispute. Certain clues suggest LRRK2 may affect the 
stability of microtubules. LRRK2 has been reported to enhance the polymerization of bovine 
tubulin in the presence of microtubule associated proteins (MAPs) in vitro (Gillardon, 
2009b). In addition, LRRK2 has been linked to canonical Wnt signaling (Berwick & Harvey, 
2012a; Lin et al., 2010; Sancho et al., 2009), which is well described as a modulator of the 
microtubule cytoskeleton in neurons (Salinas, 2007). Perhaps most strikingly though, 
numerous lines of in vivo data implicate LRRK2 in modulating the function of the MAP tau, 
best known for its role in Alzheimer’s disease (Taymans & Cookson, 2010). Post-mortem 
analysis of Parkinson’s disease brains carrying Y1699C, G2019S or I2020T PARK8 
mutations have been reported to display ‘tau pathology’ in a number of cases (Khan et al., 
2005; Rajput et al., 2006; Ujiie et al., 2012; Zimprich et al., 2004). Tau 
hyperphosphorylation has also been reported in brains from transgenic mice over-expressing 
LRRK2 with the G2019S or R1441G mutations (Li et al., 2009; Melrose et al., 2010), while 
Lrrk2 knockout has been reported to decrease tau phosphorylation (Gillardon, 2009b) 
although others have been unable to replicate this observation (Hinkle et al., 2012). G2019S 
LRRK2 has also been reported to promote tau phosphorylation in Drosophila (Lin et al., 
2010). Mechanistically, the details linking LRRK2 to tau phosphorylation are lacking but one 
might predict the interaction between LRRK2 and microtubules would bring LRRK2 and tau 
into proximity. Indeed, a recent report suggests this may be the case (Kawakami et al., 2012). 
Whether LRRK2 phosphorylates tau directly remains unclear with one supporting direct 
phosphorylation (Kawakami et al., 2012), and another suggesting that phosphorylation is 
performed by glycogen synthase kinase 3 (GSK3) (Lin et al., 2010), a reported LRRK2 
interactor (Berwick & Harvey, 2012a; Lin et al., 2010). These reports are not necessarily in 
conflict, since the experimental systems used are different and tau contains over 80 reported 
phosphorylation sites (http://cnr.iop.kcl.ac.uk/hangerlab/tautable). However, the possibility 
that phosphorylation is via GSK3 is intriguing, since this kinase has been implicated in the 
control of multiple MAPs besides tau, such as adenomatous polyposis coli (Zhou et al., 2004) 
and collapsin response 	  mediator protein 2 (Cole et al., 2004). Therefore, it is plausible that 
the control of microtubule dynamics by LRRK2 involves the modulation of a multitude of 
MAPs and takes place at a variety of microtubule sites, not just those regulated by tau in 
axons. 
Parallel to a role for LRRK2 on microtubules, LRRK2 has also been connected to the actin 
cytoskeleton via the regulation of ERM (Ezrin-Radixin-Moesin) protein phosphorylation. 
ERM proteins are three homologous proteins involved in anchoring actin filaments to the 
plasma membrane (Mangeat et al., 1999). Phosphorylation of ERM proteins is believed to 
induce a conformational change resulting in an open ‘active’ shape (Mangeat et al., 1999). 
Two groups have found a positive correlation between LRRK2 levels and ERM protein 
phosphorylation (Jaleel et al., 2007; Parisiadou et al., 2009), that is most likely mediated by 
an indirect regulation (Nichols et al., 2009). Importantly, ERM proteins are essential for 
growth cone morphology and motility (Paglini et al., 1998), thus indicating that LRRK2 also 
impacts upon neurogenesis through ERM proteins. The connection between LRRK2 and the 
actin cytoskeleton is strengthened by a mass spectrometry study which found endogenous 
LRRK2 in HEK293 cells to associate with actin and a number of proteins known to modulate 
the actin cytoskeleton (Meixner et al., 2011). In light of these observations, it is interesting to 
speculate about a role for LRRK2 in coordinating neuronal microtubule as well as actin 
networks. 
Thus, there are several lines of evidence for the importance of LRRK2 in a number of 
processes that underlie neurogenesis, but what evidence directly supports a requirement for 
LRRK2 in neurogenesis? Importantly, a comprehensive study in mouse embryos found a 
spatio-temporal LRRK2 mRNA expression pattern that is highly consistent with a key role 
for LRRK2 in neurogenesis (Zechel et al., 2010). Using in situ hybridization, LRRK2 mRNA 
expression was detected as early as day E10.5 in the developing central nervous system, with 
transcript detectable throughout the cortex by day E12.5. Crucially, the authors describe 
embryonic expression of Lrrk2 as being most prominent in brain regions with ‘high 
proliferative and migratory activity, as well as sites of differentiation and cell death’ (Zechel 
et al., 2010). These include the ventricular and subventricular zones of the telencephalon, in 
agreement with a previous report investigating older mice (Melrose et al., 2007). Lrrk2 was 
also found to be expressed in neural stem cells isolated from the dentate gyrus or striatal 
subventricular zone of E18.5 or adult mice. Thus LRRK2 expression patterns are consistent 
with a role in neurogenesis throughout life. 
It is thus unsurprising that a growing body of experimental data show defects in neurogenesis 
caused by altered LRRK2 function. Experiments in cell and animal models utilized LRRK2 
knock-down or knockout, over-expression of wild-type LRRK2, familial LRRK2 mutants 
and artificial kinase or GTPase dead mutants to measure predominantly neurite outgrowth 
and reported changes in length, number and branching of neurites in vitro and in brain slices. 
Most reports agree that the over-expression of familial LRRK2 mutants elicit decreased 
neurite length (Biosa et al., 2012; Chan et al., 2011; Cherra et al., 2012; Cho et al., 2012; 
Dächsel et al., 2010; Heo et al., 2010; Lin et al., 2010; MacLeod et al., 2006; Maekawa et al., 
2012; Parisiadou et al., 2009; Plowey et al., 2008; Ramonet et al., 2011; Sheng et al., 2012; 
Stafa et al., 2012; Winner et al., 2011). Over-expression of wild-type LRRK2 was generally 
found to have no effect, or to cause mild neurite shortening, either reaching statistical 
significance or remaining as a trend. In contrast, loss of LRRK2 appears to have the opposite 
effect, allowing longer and more branched neurites to develop (Dächsel et al., 2010; Heo et 
al., 2010; MacLeod et al., 2006; Parisiadou et al., 2009; Paus et al., 2012; Stafa et al., 2012), 
although not all studies are in agreement (Gillardon, 2009b; Meixner et al., 2011). In general, 
these studies provide overwhelming evidence that the level of LRRK2 expression impacts 
upon neuritogenesis as predicted from the LRRK2 expression pattern throughout brain 
development. 
Finally, we also note two publications investigating a role for LRRK2 in adult neurogenesis 
(Paus et al., 2012; Winner et al., 2011). These studies are of special relevance to Parkinson’s 
disease, where impaired adult neurogenesis has been implicated in the development of non-
motor symptoms (Marxreiter et al., 2012). A study in mice over-expressing the G2019S 
LRRK2 mutant reported decreased proliferation in the dentate gyrus and subventricular zones 
associated with decreased dendritic length and branching, and decreased cell survival 
(Winner et al., 2011). Another study by Paus and colleagues looked at adult neurogenesis in 
the dentate gyrus of Lrrk2 knockout mice (Paus et al., 2012). As might be predicted, 
increased dendritic length and neurite arborisation was observed. No defects in cell 
proliferation or survival were found however, although loss of Lrrk2 led to a greater number 
of doublecortin positive cells (Paus et al., 2012).  
Thus a wealth of data implicates LRRK2 as a central player in the latter stages of 
neurogenesis – in particular neurite outgrowth and synaptogenenesis – possibly via a 
combination of modulating vesicle trafficking and cytoskeleton dynamics. Nonetheless, 
emerging evidence also links LRRK2 to earlier stages of neuronal development, prior to cell 
cycle exit (Winner et al., 2011), supported by evidence of effects of LRRK2 on proliferation 
(Liu et al., 2012; Milosevic et al., 2009) and carcinogenesis (Hassin-Baer et al., 2009). Thus, 
LRRK2 might play a role from early mitotic neuronal precursors to terminal differentiation. 
As outlined above, we would suggest that LRRK2 is likely to function as a scaffolding 
protein in a number of distinct complexes, some of these important in neurogenesis. 
Nonetheless, two crucial questions remain: what is upstream of these complexes, and how are 
they regulated? 
A role for LRRK2 in Wnt signaling  
Wnt (wingless/Int) signaling pathways constitute a family of highly conserved signal 
transduction cascades that have long been established as master regulators of animal 
development (Freese et al., 2010). The relevance of these pathways to neurogenesis is beyond 
doubt and will not be reviewed in detail in this article. Nonetheless the reader should be 
aware that a growing body of data also implicates Wnt signaling in the function of mature, 
post-mitotic neurons (Inestrosa & Arenas, 2010). Moreover, deregulated Wnt signaling 
pathways are suggested pathomechanisms for a number of neurological conditions, including 
Alzheimer’s disease, Parkinson’s disease, autism and schizophrenia (Berwick & Harvey, 
2012b; De Ferrari & Moon, 2006; Inestrosa & Toledo, 2008). Thus Wnt cascades can be 
considered essential for the central nervous system at all stages of life. 
Wnt ligands themselves are secreted glycoproteins that bind to the extracellular domains of 
frizzled receptors on the plasma membrane of target cells. Signaling specificity is achieved in 
part through the large repertoire of Wnt ligands and frizzled receptors expressed in higher 
organisms, but also through the involvement of co-receptors. In the case of the canonical Wnt 
pathway, these receptors are low density lipoprotein receptor-like proteins 5 and 6 (LRP5/6), 
which have also been reported to bind Wnt ligands at the cell surface. Upon binding of Wnt 
ligands to frizzled receptors and associated co-receptors the signal is relayed across the 
membrane, resulting in the activation of one or more intracellular cascades. Wnt signaling 
pathways relevant to neurogenesis and/or the function of mature neurons are depicted in 
Figure 3. 
The best-described Wnt signaling cascade is the canonical Wnt pathway. This signaling 
mechanism ultimately results in the activation and nuclear recruitment of β-catenin protein, 
leading to the modulation of downstream target genes. In consequence, this pathway is 
sometimes referred to as the Wnt-β-catenin pathway. Canonical Wnt signaling is an unusual 
signaling mechanism as several events take place in the absence of a stimulus. In particular, 
β-catenin is sequestered into an inhibitory cytosolic complex known as the β-catenin 
destruction complex. Here, β-catenin is phosphorylated by GSK3 (the same protein 
implicated in tau phosphorylation). β-catenin phosphorylation results in the targeting of β-
catenin for degradation by the proteosome. Therefore, in the absence of canonical Wnt 
pathway activators, β-catenin is continually degraded, and consequently unable to accumulate 
in the nucleus to regulate gene expression. Binding of Wnt ligand to frizzled receptors and 
LRP5/6 results in the recruitment of cytosolic dishevelled (DVL) proteins (key intermediates 
of most Wnt signaling branches) to the plasma membrane. Via interaction with key 
components of the β-catenin destruction complex such as Axin, DVL proteins cause the 
subsequent relocalization of the β-catenin destruction complex to the same juxtamembrane 
site. This elicits the penultimate stage of canonical Wnt signaling, the inhibition of β-catenin 
phosphorylation, which allows β-catenin to become proteasome resistant and thus accumulate 
throughout the cell. However, the complexity of this mechanism is emerging. A requirement 
for the internalization of the cell membrane associated protein complex containing Wnt 
ligand, frizzled receptor, LRP5/6, DVL proteins and the β-catenin destruction complex into 
the endosomal system is now widely accepted. This internalized signaling complex passes 
through the endosomal system where it continues to signal from the cytosolic face of 
intracellular membranes (the so-called ‘signalosome’ hypothesis). Finally, the signalosomes 
are sequestered from the cytosol into multi-vesicular bodies. Traditionally, by analogy to 
growth factor signaling pathways, this has been considered the termination step in Wnt 
signaling. However, recent data suggest that the sequestration of signalosomes into multi-
vesicular bodies constitutes a final ‘signal activation’ mechanism, since this leads to the 
removal of the canonical Wnt signaling pool of GSK3 from the cytosol (Dobrowolski & De 
Robertis, 2012).  
Data from our laboratory has strongly implicated LRRK2 in multiple aspects of the canonical 
Wnt pathway. This work arose from a yeast-two-hybrid screen identifying interactors of the 
Roc and/or COR domains of LRRK2 (Sancho et al., 2009). Since Roc and COR domains are 
expressed together throughout nature (Marín et al., 2008), it is reasonable to consider both 
domains part of a single functional unit conferring GTPase activity that was termed the 
RocCOR tandem domain. Using this LRRK2 RocCOR tandem domain as bait, the yeast-two-
hybrid screen returned cDNAs encoding the human dishevelled proteins DVL2 and DVL3 as 
potential interactors. Subsequent  assays confirmed a direct interaction between the LRRK2 
RocCOR domain and all three human DVL proteins, with the interaction site mapped to the 
dishevelled-Egl10-pleckstrin (DEP) domain of DVL1-3 (Sancho et al., 2009). Co-
immunoprecipitation experiments confirmed that LRRK2 associates with DVL proteins in 
mammalian cells, while confocal microscopy revealed a striking recruitment of LRRK2 into 
polymeric DVL structures that are induced by over-expression of these proteins (Sancho et 
al., 2009).  
Since DVL proteins are essential intermediates of all major branches of Wnt signaling (Fig. 
3), our work opened the possibility that LRRK2 may function in multiple Wnt cascades. 
However, follow-up studies focused on the canonical Wnt pathway, which can be assayed 
easily using TOPflash assays (Veeman et al., 2003). TOPflash assays are luciferase-based 
reporter assays that quantitatively determine the level of β-catenin-mediated transcriptional 
activity in cells. Importantly, TOPflash assays revealed the LRRK2-DVL protein interaction 
to be functional as well as physical, since co-transfection of LRRK2 protein with any of the 
three human DVL proteins resulted in an enhancement of DVL-driven canonical Wnt activity 
(Berwick & Harvey, 2012a). This effect required the kinase and GTPase activities of LRRK2 
and was increased further by targeting LRRK2 (and presumably, therefore, the LRRK2-DVL 
interaction) to membranes. Interestingly, Wnt3a treatment was found to increase the amount 
of endogenous LRRK2 present in membrane fractions of HEK293 cells (Berwick & Harvey, 
2012a). Since the activation of canonical Wnt signaling takes place at intracellular 
membranes – consistent with the signalosome hypothesis – this lead us to investigate whether 
LRRK2 might physically interact with Wnt signaling receptors. Using a combination of 
confocal microscopy and co-immunoprecipitation LRRK2 was discovered to associate with 
LRP6, but not frizzled-1, frizzled-4 or frizzled-5. Yeast-two-hybrid assays confirmed that the 
interaction was direct and, similar to interaction with DVL proteins, involved the LRRK2 
RocCOR tandem domain (Berwick & Harvey, 2012a). These data are consistent with a role 
for LRRK2 in the activation of canonical Wnt signaling bringing DVL proteins to cellular 
membranes. 
However, somewhat counter-intuitively, knock-down of LRRK2 was also found to potentiate 
DVL-driven TOPflash activity (Berwick & Harvey, 2012a). A similar effect was observed on 
basal and Wnt3a-driven β-catenin activity. In this regard knockdown of LRRK2 mimicked 
knockdown of AXIN1, an established component of the β-catenin destruction complex. Loss 
of AXIN1 is well known to disrupt the β-catenin destruction complex thereby compromising 
β-catenin degradation and leading to an increase in basal canonical Wnt activity. We 
therefore wondered whether loss of LRRK2 might compromise an inhibitory role for LRRK2 
in the β-catenin destruction complex. Consistent with this, co-immumoprecipitation of 
endogenous protein from mouse brain revealed Lrrk2 to exist in complex with multiple 
components of the β-catenin destruction complex, including GSK3 and β-catenin. Taken 
together, these results suggest a role for LRRK2 as a scaffold in canonical Wnt signaling. In 
the basal state, LRRK2 functions as part of the cytosolic β-catenin destruction complex and 
loss of LRRK2 compromises this role, leading to disruption of the complex and pathway 
activation. Following stimulation of cells with Wnt ligand, LRRK2 is recruited to cellular 
membranes. Here, via interaction with DVL proteins, the β-catenin destruction complex and 
LRP6, LRRK2 assists in the formation of Wnt signalosomes, enhancing the Wnt signal 
activity. 
Our data are supported by work from other laboratories. Most notably, supporting the idea 
that LRRK2 associates with the β-catenin destruction complex, an interaction between 
LRRK2 and GSK3 has been reported in Drosophila (Lin et al., 2010). While this report does 
not investigate which cellular GSK3 pool associates with LRRK2 we note that the interaction 
modulated tau phosphorylation. Since Wnt signaling is well known to regulate the 
phosphorylation of tau by GSK3 (Hooper et al., 2008), this would suggest that the GSK3 
pool found to bind LRRK2 by Lin and co-workers could indeed represent the same Wnt-
responsive fraction identified in our study (Berwick & Harvey, 2012a; Lin et al., 2010). 
Perhaps most interesting in this report, the LRRK2-GSK3 interaction was shown to be 
enhanced by the G2019S PARK8 mutation (Lin et al., 2010). Curiously, the strength of the 
LRRK2 interaction with both DVL proteins and LRP6 was also affected by PARK8 
mutations (Berwick & Harvey, 2012a; Sancho et al., 2009). Unsurprisingly therefore, all 
investigated PARK8 mutations decreased the capacity of LRRK2 to enhance the β-catenin 
activation elicited by DVL proteins (Berwick & Harvey, 2012a). This observation has 
obvious implications for the pathogenesis of Parkinson’s disease, where perturbed Wnt 
signaling has already been suggested as a candidate pathomechanism (Berwick & Harvey, 
2012b). However, as we outline below, decreased canonical Wnt signaling associated with 
familial PARK8 mutations suggests that transgenic LRRK2 animal models of Parkinson’s 
disease might present with discrete developmental phenotypes associated with Wnt 
dysfunction. 
In addition to studies linking LRRK2 to Wnt signaling by protein-protein interaction strong 
circumstantial evidence from transcriptomics studies support this notion. In particular, an 
investigation into the effect of LRRK2 knockdown in human SH-SY5Y cells found mRNA 
species encoding a number of Wnt signaling proteins to be altered (Häbig et al., 2008). As it 
is well described that many Wnt signaling components are regulated at the transcriptional 
level by pathway activation, knockdown of LRRK2 would be expected to alter expression of 
other Wnt signaling proteins. Data from C.elegans also support this observation, with mRNA 
transcripts encoding Wnt signaling proteins being described as ‘coregulated with LRRK2’ 
(Ferree et al., 2011).  
Further support, albeit indirect, of a role for LRRK2 in Wnt signaling comes from studies 
investigating altered gene expression in animal models of Parkinson’s disease. These 
investigations used a variety of different neurotoxins to elicit dopaminergic cell death 
resulting in Parkinsonian-like motor phenotypes. L’Episcopo and colleagues reported 
increased Wnt1 gene expression as well as deregulated Fzd1 and β-catenin expression in the 
ventral midbrain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated mice 
(L'Episcopo et al., 2011). These experiments support the idea that canonical Wnt signal 
activation via increased Wnt1 expression in astrocytes is neuroprotective (L'Episcopo et al., 
2011). Another study used 6-hydroxydopamine (6-OHDA) to induce dopaminergic cell death 
in rats resulting in increased expression of the Wnt signal inhibitor Dickkopf-1 (Dkk1) (Dun 
et al., 2012). Both models are in agreement with a neuroprotective role for Wnt signaling, 
since treatment with Dkk1 exacerbated toxic effects, whilst GSK3 inhibition was found to be 
protective (L'Episcopo et al., 2011; Dun et al., 2012). An unbiased genome-wide RNAseq 
approach in mice treated with a variety of pesticides showed altered expression of mRNAs 
encoding Wnt signaling components in ventral midbrain and striatum (Gollamudi et al., 
2012). Exposure to pesticides is a well known environment risk factor for Parkinson’s 
disease, further suggesting that dysregulated Wnt signaling might be a common mechanism 
underlying dopaminergic cell death in Parkinson’s disease. Expression studies in human 
Parkinson’s disease brains have not been as conclusive, although it is important to note that 
altered expression of Wnt pathway genes has been reported in women but not in men 
(Cantuti-Castelvetri et al., 2007). These studies need to take into account that the brains 
analysed are usually from individuals with symptomatic Parkinson’s disease reflecting the 
loss of the majority of dopaminergic neurons in the substantia nigra. Therefore gene 
expression changes are likely no longer reflective of the initial underlying etiology. However, 
in addition to work on LRRK2 outlined above, other clues from genetic causes of Parkinson’s 
disease are consistent with altered Wnt signaling. Most notably Parkin, the product of the 
PARK2 gene, has been reported to inhibit canonical Wnt signaling (Rawal et al., 2009), 
whilst the transcription factor Nurr1, which has been strongly linked to Parkinson’s disease, 
is regulated by β-catenin (Jankovic et al., 2005; Kitagawa et al., 2007). Finally, it is not just 
Parkinson’s disease-related genes that have been associated with Wnt signaling; Wnt 
signaling genes themselves have been linked to risk of Parkinson’s disease. In particular, 
GSK3β has been suggested to modify disease risk in two studies (Kalinderi et al., 2011; 
Kwok et al., 2005) although a third failed to find any affect (Wider et al., 2011). 
In summary therefore, LRRK2 binds three central Wnt signaling components (Berwick & 
Harvey, 2012a; Lin et al., 2010; Sancho et al., 2009), while loss of LRRK2 and pathogenic 
PARK8 mutations impact upon the activity of the canonical Wnt pathway (Berwick & 
Harvey, 2012a). In addition, connections between LRRK2 and Wnt cascades are strengthened 
by a number of studies supporting a role for dysregulated Wnt signaling in the early stage of 
Parkinson’s disease. As outlined above, there is overwhelming evidence for a central function 
for LRRK2 in neurogenesis. Combining these ideas, we postulate a specific role for LRRK2 
in Wnt-mediated neurogenesis. In the final section of this article we will elaborate on this and 
suggest experimental approaches to test our hypothesis. 
LRRK2 as a major player in Wnt-mediated neuronal differentiation? 
It is beyond dispute that Wnt ligands represent potent morphogens required for numerous 
aspects of neurogenesis, in particular to the development of dopaminergic neurons of the 
ventral midbrain (Brault et al., 2001; Carpenter et al., 2010; Castelo-Branco et al., 2010; 
Castelo-Branco et al., 2004; Castelo-Branco et al., 2003; Parish et al., 2008). Degeneration of 
these neurons underlies the typical motor symptoms associated with Parkinson’s disease 
(Berwick & Harvey, 2012b). In this context, deregulated Wnt signaling caused by PARK8 
mutations might cause subtle defects in establishing neuronal circuitries, leaving these 
dopaminergic neurons more vulnerable to additional insults important for the pathogenesis of 
Parkinson’s disease. In the remainder of this review we describe roles for Wnt signaling 
pathways in modulating the same neurogenic events that were reported to be influenced by 
LRRK2. Combined with evidence of a function for LRRK2 as a Wnt signaling scaffold, this 
further supports the idea that LRRK2 is a central player in Wnt-mediated neurogenesis.  
Evidence that Wnt ligands are major regulators of synaptic vesicle trafficking and 
synaptogenesis is accumulating (Farías et al., 2010; Inestrosa & Arenas, 2010). Published 
data support pre-synaptic and post-synaptic effects of multiple branches of Wnt signaling. 
Mammalian pre-synaptic development appears particularly dependent on Wnt-7a, an agonist 
of the canonical Wnt pathway (Farías et al., 2010). This Wnt ligand appears to be required 
for normal expression of the pre-synaptic vesicle protein, Synapsin 1, in the developing 
mouse brain (Hall et al., 2000), with similar effects seen in mature neurons (Farías et al., 
2007). Treatment of cultured neurons with dickkopf 1, an LRP5/6 antagonist, has confirmed 
this pre-synaptic effect of Wnt7a is through the canonical pathway (Davis et al., 2008). 
Curiously though, data from a number of laboratories suggest this effect is independent of 
transcription (Farías et al., 2010). This observation has led to the cascade by which Wnt7a 
modulates pre-synaptic and axonal (see below) function being described as a ‘divergent’ 
canonical cascade (Ciani et al., 2004). Interestingly, LRRK2 is not just a key Wnt signaling 
protein interacting with LRP6 but was also found to interact with synapsin-1 and play a role 
in synaptic vesicle trafficking (Piccoli et al, 2011). The above evidence supports the idea of a 
Wnt7a-induced LRRK2-mediated canonical Wnt pathway with a direct transcriptionally 
independent effect on synapse formation and maintenance. 
Both LRRK2 and Parkinson’s disease pathogenesis have been linked to macroautophagy. In 
addition, there is also evidence consistent with the idea that macroautophagy is modulated by 
Wnt ligands. Strikingly, knock-down of β-catenin alone appears sufficient to induce 
macroautophagy in carcinoma cells (Chang et al., 2012). Correspondingly, acute treatment of 
hippocampal neurons with the β-catenin agonist 2-amino-4-[3,4-(methylenedioxy)benzyl-
amino]-6-(3-methoxyphenyl)pyrimidine (Liu et al., 2005) was found to reduce oxygen-
glucose deprivation induced macroautophagy (Wang et al., 2012). Taken together, these 
observations suggest β-catenin to be a negative regulator of macroautophagy. In addition, 
GSK3 activity almost certainly impacts upon macroautophagy. GSK3 has recently been 
reported to phosphorylate TIP60, a histone acetyl transferase required for induction of 
macroautophagy. Mutation of the reported phosphorylation site to an alanine residue is 
sufficient to prevent growth factor deprivation-induced macroautophagy (Lin et al., 2012). In 
agreement with this, intranasal treatment with a GSK3 inhibitor peptide was reported to result 
in decreased autophagy and increased lysosomal acidification in brains from an Alzheimer’s 
disease transgenic mouse model (Avrahami et al., 2013), with similar results obtained in 
vitro. These data predict a model where canonical Wnt pathway activation – resulting in 
GSK3 inhibition and β-catenin accumulation – would lead to decreased macroautophagy. 
However, the events do not appear straightforward, since GSK3 inhibition in a neuroblastoma 
cell line has been reported to induce increased lysosomal biogenesis, leading to increased 
macroautophagic flux (Parr et al., 2012). There are numerous reasons for this potential 
discrepancy, for example cell lines and treatments used, however it is perhaps more relevant 
to observe that these studies are at very early stages. More pertinently still, none look at the 
regulation of macroautophagy during neural differentiation, where one would expect the 
requirements placed on the autophagic machinery of developing neurons to be more subtle 
than under conditions of stress. In conclusion, even though evidence supports the importance 
for LRRK2 and canonical Wnt signaling in macroautophagy, the specific signal transduction 
cascade, especially during neuronal differentiation, requires further investigation. 
Wnt signaling is well-known to influence the dynamic instability of the microtubule 
cytoskeleton (Salinas, 2007). Multiple proteins involved in both the canonical and non-
canonical Wnt pathway have been reported to affect microtubule stability, whilst GSK3 
phosphorylates a variety of microtubule associated proteins (Cole et al., 2004; Kim et al., 
2011; Salinas, 2007; Zhou et al., 2004). Modulation of microtubule structures by Wnt 
pathways appear common to multiple cell types, for example Wnt ligands appear to be key 
regulators of mitotic spindles (Walston et al., 2004). In light of the above-described  
presynaptic function of LRRK2 and Wnt7a, it is important to emphasize that a large number 
of studies showing Wnt-mediated regulation of microtubules have used axon outgrowth as 
the model system. Much of this work was initiated by the observation that Wnt7a elicits 
axonal spreading and branching in cultured cerebellar granule cells (Lucas & Salinas, 1997), 
with corroborating data soon obtained in vivo (Hall et al., 2000). This effect is mimicked by 
GSK3 inhibitors and likely involves inhibition of phosphorylation of the microtubule 
associated protein MAP1B (Lucas et al., 1998; Lucas & Salinas, 1997). Additional 
mechanisms involved in Wnt-mediated control of axonal microtubules include the 
identification of the β-catenin destruction complex members adenomatous polypsis coli 
(APC) and AXIN1 as microtubule binding proteins in axons (Ciani et al., 2004; Purro et al., 
2008). The precise details are still being elucidated, but it is fair to assume that, via 
interaction with microtubules, APC and AXIN1 create a spatially controlled signaling 
mechanism, specific to growing axons and growth cones. Importantly, LRRK2 also interacts 
with microtubules, induces hyperphosphrylation of the axonal MAP tau (Biskup et al., 2006; 
Dzamko et al., 2010; Gandhi et al., 2008; Gillardon, 2009a; Gillardon, 2009b; Gloeckner et 
al., 2006; Kawakami et al., 2012; Kett et al., 2012; Sancho et al., 2009; Sheng et al., 2012), 
interacts with components of the β-catenin destruction complex (Berwick & Harvey, 2012a; 
Lin et al., 2010) and co-localizes with DVL1 to neurites in cell culture models at early stages 
of differentiation (Sancho et al, 2009). This further supports the idea of a LRRK2 mediated 
Wnt signaling pathway important during neuronal differentiation. 
Above we have established good evidence for roles of LRRK2 and Wnt signaling in the 
regulation of pre-synaptic vesicle trafficking and microtubule dynamics, processes crucial for 
axonal outgrowth and synpatogenesis. While the evidence of a role for LRRK2 in 
macroautophagy is overwhelming, data supporting a role for Wnt signaling in modulating 
this process are more circumstantial. Nonetheless, the hypothesis that LRRK2 might function 
specifically in Wnt-mediated neuritogenesis is plausible, especially for the latter stages of 
neurogenesis. But what about the earlier stages? Here, the role for Wnt signaling is beyond 
doubt. For example, treatment with Wnt1, which activates the canonical Wnt pathway, causes 
expansion of ventral midbrain precursors (Castelo-Branco et al., 2003). Conversely, loss of 
Wnt1 in mice leads to a complete failure of mid- and hind-brain precursors to expand, leading 
to a near absence of these brain regions (Thomas & Capecchi, 1990). Similarly, Wnt3a 
(another canonical pathway agonist) secreted by hippocampal astrocytes has been shown to 
be essential for adult neurogenesis in the dentate gyrus (Lie et al., 2005). By contrast 
evidence of a function for LRRK2 in the proliferation of neural precursors and in adult 
neurogenesis are promising but at an early stage (Milosevic et al., 2009; Winner et al., 2011). 
In conclusion, there is a remarkable degree of overlap between the effects of Wnt signaling 
and LRRK2 on neurogenesis. The importance of LRRK2 in canonical Wnt signaling further 
supports the notion of a specific function for LRRK2 in Wnt-mediated neurogenesis. This 
hypothesis can be investigated by crossing the relevant transgenic animals with known 
defects in Wnt-mediated neuronal differentiation with LRRK2 transgenics looking for an 
enhancement or rescue of phenotype. Of course, such experiments come with the usual 
important caveats associated with using animal models. For example, long non-coding RNAs 
are known to be poorly conserved between species making their study in model organisms of 
questionable relevance to humans (Pang et al., 2006). Human-specifc transcriptional 
networks have also been reported in the brain (Konopka et al., 2012). However at the level of 
protein function, conservation across species is usually very high, and thus, even though the 
data should be treated with caution, crossing of transgenic animal models is a justifiable 
approach. Indeed, this strategy has proven particularly useful for unveiling milder 
neurodevelopmental phenotypes. For example, crossing of Wnt7a and Dvl1 knockout mice 
allowed a requirement for these genes in the development of cerebellar glomerular rosettes to 
be uncovered (Ahmad-Annuar et al., 2006). As Lrrk2 knockout and familial PARK8 mutant 
transgenic mice likely represent models of subtly increased and decreased canonical Wnt 
signaling, respectively, crossing of these lines with Wnt7a and/or Dvl1 knockout animals 
would be of great interest.  
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Figure Legends 
Figure 1. Domain Structure of LRRK2. Domains are color-coded according to function: those 
implicated in protein-protein interaction are depicted in blue; domains involved in GTPase function 
are green; and the kinase domain red. Here, LRRK2 is depicted as a dimer, although LRRK2 also 
exists as monomers and in higher molecular weight complexes (Greggio et al., 2008). Dimerization is 
likely to be mediated by the COR and/or WD40 domains (double-headed arrows). COR domains are 
established as dimerization devices in ROCO proteins (Gotthardt et al., 2008), whilst ablation of the 
WD40 domain has been reported to disrupt LRRK2 dimerization (Jorgensen et al., 2009). The 
location of pathological mutations proven to segregate with Parkinson’s disease are shown with 
asterisks and bold font. Although only considered a risk factor, the G2385R mutation is also depicted 
with a plus sign, since this mutation is mentioned in the main text and is very frequent amongst Asian 
populations. Abbreviations: ARM, armadillo repeat; ANK, ankyrin repeat; LRR, leucine-rich repeat; 
Roc, ras of complex proteins; COR, c-terminal of Roc; Kin, kinase. 
Figure 2. LRRK2 Regulates Cell Biological Functions Important for Neurogenesis. Several lines 
of evidence support roles for LRRK2 in microtubule function, endocytosis/vesicle trafficking and 
autophagy. LRRK2 is likely to impact upon neurite outgrowth and the latter stages of neurogenesis 
through direct association with membrane structures and microtubules and/or regulation of signaling 
pathways. In addition, LRRK2 has been implicated in proliferation and may therefore also govern 
early stages of neurogenesis. The interaction between microtubule function, vesicle trafficking, 
autophagy and proliferation and the canonical Wnt pathway is depicted but other pathways are likely 
to play additional roles. 
Figure 3. Overview of Wnt Signaling Pathways. The three major branches of Wnt signaling – the 
canonical, planar cell polarity (PCP), and Wnt-Ca2+ – pathways are illustrated. Note that in growing 
neurites a further branch has been reported, the so-called divergent canonical pathway, which impacts 
upon microtubule stability. Abbreviations: APC, adenomatous polyposis coli; CaN, calcineurin; CK1, 
casein kinase 1; DAAM, dishevelled-associated activator of morphogenesis; DVL, dishevelled; FzR, 
frizzled receptor; GSK3, glycogen synthase kinase 3; JNK, c-Jun n-terminal kinase; LRP5/6, low-
density lipoprotein receptor-related protein 5/6; NFAT, nuclear factor of activated T-cells; PKC, 
protein kinase C; PLC, phospholipase C; ROCK, Rho-associated protein kinase. 
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